Global Lymphopenia Therapeutics Market Report 2019-2023 with Sales Data for Acquired Lymphopenia & Inherited Lymphopenia Products

Monday, 21. October 2019 10:50

Dublin, Oct. 21, 2019 (GLOBE NEWSWIRE) -- The "Lymphopenia Therapeutics Market by Product and Geography - Forecast and Analysis 2019-2023" report has been added to ResearchAndMarkets.com's offering.

The lymphopenia therapeutics market analysis considers sales from acquired lymphopenia and inherited lymphopenia product segments. The analysis also considers the sales of lymphopenia therapeutics in Asia, Europe, North America, and RoW.

In 2018, the acquired lymphopenia segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the rising incidence of diseases from various therapy areas such as blood cancer and autoimmune disorders will play a significant role in the acquired lymphopenia segment to maintain its market position.

The market report looks at factors such as increasing risk factors for lymphopenia. However, adverse effects associated with therapeutics, high cost of therapeutics, and stringent regulations may hamper the growth of the lymphopenia therapeutics industry over the forecast period.

Increasing risk factors for lymphopenia

High prevalence of risk factors such as inherited diseases, autoimmune disorders, blood cancer or blood diseases, and infectious diseases such as AIDS has led to the reduction in lymphocyte counts in blood of a patient. This increases the incidence of lymphopenia.

Pharmaceutical companies are investing in research and development activities to come up with effective and cost-efficient therapeutic drugs for lymphopenia. The availability of these drugs will lead to the expansion of the global lymphopenia therapeutics market at a CAGR of almost 4% during the forecast period.

Strategic alliances

Vendors are focusing on addressing the issues associated with high cost of research and development activities of therapeutic drugs by collaborating with pharmaceutical companies. They are also expanding their distribution networks by entering strategic alliances with other vendors. As a result, the development and commercialization of advanced therapies and drugs for lymphopenia is increasing. This development is expected to have a positive impact on the overall market growth.

Competitive Landscape

With the presence of several major players, the global lymphopenia therapeutics market is fragmented. The robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading lymphopenia therapeutics manufacturers, that include:

  • AbbVie Inc.
  • Bristol-Myers Squibb Co.
  • CSL Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline PLC
  • Grifols S.A.
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Sanofi

Also, the lymphopenia therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

Key Topics Covered

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Comparison by product
  • Acquired lymphopenia - Market size and forecast 2018-2023
  • Inherited lymphopenia - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • RoW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DRIVERS AND CHALLENGES

PART 10: MARKET TRENDS

  • Increasing research in regenerative medicines
  • Strategic alliances
  • Presence of patient assistance programs

PART 11: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 12: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AbbVie Inc.
  • Bristol-Myers Squibb Co.
  • CSL Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline PLC
  • Grifols S.A.
  • Johnson & Johnson Services Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Sanofi

For more information about this report visit https://www.researchandmarkets.com/r/p0fl2w

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900

Primary Logo

Related Links: 
Author:
Copyright GlobeNewswire, Inc. 2016. All rights reserved.
You can register yourself on the website to receive press releases directly via e-mail to your own e-mail account.